Heitz F - Search Results

1

Perception of side effects associated with anticancer treatment in women with breast or ovarian cancer (KEM-GO-1): a prospective trial.

Ataseven B, Frindte J, Harter P, Gebers G, Vogt C, Traut A, Breit E, Bluni V, Reinisch M, Heitz F, Kostara A, Kuemmel S, Prader S, Bommert M, Schneider S, du Bois A. Ataseven B, et al. Among authors: heitz f. Support Care Cancer. 2020 Aug;28(8):3605-3615. doi: 10.1007/s00520-019-05216-y. Epub 2019 Dec 11. Support Care Cancer. 2020. PMID: 31828488

2

Role of cytoreductive surgery in recurrent ovarian cancer.

Harter P, Hilpert F, Mahner S, Kommoss S, Heitz F, du Bois A. Harter P, et al. Among authors: heitz f. Expert Rev Anticancer Ther. 2009 Jul;9(7):917-22. doi: 10.1586/era.09.49. Expert Rev Anticancer Ther. 2009. PMID: 19589031 Review.

3

Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases.

Heitz F, Harter P, Lueck HJ, Fissler-Eckhoff A, Lorenz-Salehi F, Scheil-Bertram S, Traut A, du Bois A. Heitz F, et al. Eur J Cancer. 2009 Nov;45(16):2792-8. doi: 10.1016/j.ejca.2009.06.027. Epub 2009 Jul 28. Eur J Cancer. 2009. PMID: 19643597

4

Prognostic impact of additional extended surgical procedures in advanced-stage primary ovarian cancer.

Kommoss S, Rochon J, Harter P, Heitz F, Grabowski JP, Ewald-Riegler N, Haberstroh M, Neunhoeffer T, Barinoff J, Gomez R, Traut A, du Bois A. Kommoss S, et al. Among authors: heitz f. Ann Surg Oncol. 2010 Jan;17(1):279-86. doi: 10.1245/s10434-009-0787-8. Epub 2009 Nov 7. Ann Surg Oncol. 2010. PMID: 19898901

5

Prognostic factors for complete debulking in first- and second-line ovarian cancer.

Harter P, Hilpert F, Mahner S, Kommoss S, Heitz F, Pfisterer J, du Bois A. Harter P, et al. Among authors: heitz f. Int J Gynecol Cancer. 2009 Dec;19 Suppl 2:S14-7. doi: 10.1111/IGC.0b013e3181bffb3f. Int J Gynecol Cancer. 2009. PMID: 19955907 Review.

6

Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs.

Harter P, Hilpert F, Mahner S, Heitz F, Pfisterer J, du Bois A. Harter P, et al. Among authors: heitz f. Expert Rev Anticancer Ther. 2010 Jan;10(1):81-8. doi: 10.1586/era.09.165. Expert Rev Anticancer Ther. 2010. PMID: 20014888 Review.

7

Abdominal wall metastases in patients with ovarian cancer after laparoscopic surgery: incidence, risk factors, and complications.

Heitz F, Ognjenovic D, Harter P, Kommoss S, Ewald-Riegler N, Haberstroh M, Gomez R, Barinoff J, Traut A, du Bois A. Heitz F, et al. Int J Gynecol Cancer. 2010 Jan;20(1):41-6. doi: 10.1111/IGC.0b013e3181c443ba. Int J Gynecol Cancer. 2010. PMID: 20057285

8

Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy.

Heitz F, Harter P, Ewald-Riegler N, Papsdorf M, Kommoss S, du Bois A. Heitz F, et al. Expert Rev Anticancer Ther. 2010 Jul;10(7):1125-36. doi: 10.1586/era.10.53. Expert Rev Anticancer Ther. 2010. PMID: 20645701 Review.

9

Cerebral metastases in metastatic breast cancer: disease-specific risk factors and survival.

Heitz F, Rochon J, Harter P, Lueck HJ, Fisseler-Eckhoff A, Barinoff J, Traut A, Lorenz-Salehi F, du Bois A. Heitz F, et al. Ann Oncol. 2011 Jul;22(7):1571-1581. doi: 10.1093/annonc/mdq625. Epub 2010 Nov 8. Ann Oncol. 2011. PMID: 21059640 Free article.

10

Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer.

Harter P, Muallem ZM, Buhrmann C, Lorenz D, Kaub C, Hils R, Kommoss S, Heitz F, Traut A, du Bois A. Harter P, et al. Among authors: heitz f. Gynecol Oncol. 2011 Jun 1;121(3):615-9. doi: 10.1016/j.ygyno.2011.02.014. Epub 2011 Mar 17. Gynecol Oncol. 2011. PMID: 21414656

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

481 results

Search Page

Filters